Jump to content

Lomevactone

From Wikipedia, the free encyclopedia
Lomevactone
Clinical data
ATC code
  • None
Identifiers
  • 4-(4-Chlorophenyl)-6-methyl-3-phenyltetrahydro-2H-pyran-2-one
CAS Number
  • 81478-25-3
    (3R,4R,6R): 82510-81-4
    rel-(3R,4R,6R): 75115-73-0
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC18H17ClO2
Molar mass300.78g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)C2C(C(=O)OC(C)C2)c3ccccc3

Lomevactone(INN;developmental code nameDR-250) is adrugdescribed as apsychostimulantandantidepressantwhich wassynthesizedand assayed in the 1980s, but was never marketed.[1][2]

Stereoisomers

[edit]

There are eight possiblestereoisomersof lomevactone. It is the (3R,4R,6R)-form that has the psychotherapeutic properties.[3][4]

(3R,4R,6R)-Lomevactone

Synthesis

[edit]

The conjugate 1,4-alkylation reaction between 4-chlorobenzylideneacetone (1) andphenylacetonitrile(2) gives 3-(4-chlorophenyl)-5-oxo-2-phenylhexanenitrile (3). The selective reduction of the keto group to the alcohol withsodium borohydridegives 3-(4-chlorophenyl)-5-hydroxy-2-phenylhexanenitrile (4). Hydrolysis of the nitrile to an acid gives 3-(4-chlorophenyl)-5-hydroxy-2-phenylhexanoic acid. This is followed by lactone formation completing the synthesis of lomevactone (5).

Synthesis:[5]Patents:[6][7]

References

[edit]
  1. ^David J. Triggle (1997).Dictionary of pharmacological agents.London: Chapman & Hall.ISBN0-412-46630-9.
  2. ^Poncelet M, Chermat R, Soubrie P, Simon P (1983). "The progressive ratio schedule as a model for studying the psychomotor stimulant activity of drugs in the rat".Psychopharmacology.80(2): 184–9.doi:10.1007/BF00427967.PMID6136063.S2CID2372145.
  3. ^Axiotis, S.; Druex, J.; Perrin, M.; Royer, J. (1982). "Conformations in the tetrahydropyran-2-one ring". Tetrahedron. 38 (4): 499–504. doi:10.1016/0040-4020(82)80093-8.
  4. ^Axiotis, S., Sollier, J.-C., Dreux, J., Chermat, R., Poncelet, M., Simon, P. (July 1987). "Tétrahydropyrones-2 III. Recherche d'une activité psychostimulante spécifique".European Journal of Medicinal Chemistry.22(4): 293–303.doi:10.1016/0223-5234(87)90266-2.
  5. ^Axiotis, S. et al, Eur. J. Med. Chem.-Chim. Ther., 1981, 16, 431, 439.
  6. ^Pierre Simon & Jacques Dreux,U.S. patent 4,287,206(1981 to Sanofi Aventis France).
  7. ^시몽 삐에르 & 드로 짝끄, KR830002288 (1983).